RA0442

antibody from Oursmab

Targeting: KIR3DL1 AMB11, CD158E1, CD158e1/2, CD158e2, cl-11, cl-2, KIR, nkat3, NKB1, NKB1B

Western blot (Data presented on provider website)

ELISA (Data presented on provider website)

Immunocytochemistry (Recommended by provider)

Flow cytometry (Recommended by provider)

Functional assay (Recommended by provider)

Antibody Data

Product number

RA0442

Provider

Oursmab

Product name

Lirilumab (Biosimilar Reference Antibody) (KIRD2)

Antibody type

Monoclonal

Description

Lirilumab (also known as IPH-2102/BMS-986015) is a fully human monoclonal antibody that functions as an antagonist of killer cell immunoglobulin-like receptors (KIRs), specifically targeting the inhibitory receptors KIR2DL-1, -2, and -3 on natural killer (NK) cells and some T-cell subsets. By blocking these inhibitory KIRs, lirilumab prevents their interaction with their ligands (specific HLA-C allotypes) on tumor cells, thereby releasing the ¡°brake¡± on NK cell activity. This aims to enhance NK cell-mediated killing of tumor cells, a mechanism known as ¡°missing-self¡± recognition. It has been investigated clinically as an immuno-oncology agent, primarily in hematologic malignancies such as acute myeloid leukemia (AML) and multiple myeloma, often in combination with other therapies.

Reactivity

Human

Isotype

IgG

Vial size

100 ¦Ìg,1 mg,5 mg-500,10 mg,25 mg,50 mg,491 mg

Concentration

Bottled at the concentration indicated on the vial.

Storage

store at -20¡ãC or -80¡ãC. Avoid repeated freeze.